B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

13.69 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent Biosolutions

< Previous 1 2 3 4 5 6 7 Next >
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
From Emergent BioSolutions
Via Globe NewsWire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Emergent BioSolutions (EBS) Q3 2022 Earnings Call Transcript
EBS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
From Emergent BioSolutions
Via Globe NewsWire
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
From Emergent BioSolutions
Via Globe NewsWire
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
From Emergent BioSolutions
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
EXCLUSIVE: SAB Biotherapeutics Posts Wider Quarterly Loss, Cash Runway Expected Into Mid-2023
SAB Biotherapeutics' (NASDAQ: SABS) Q3 net loss reached $(7.1) million, equivalent to an EPS loss of $(0.16), as compared to a net loss of $(4.1) million a year ago. Cash and cash equivalents were $8.3... 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals
 
Via Benzinga
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies 
From Emergent BioSolutions
Via Globe NewsWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target
 
Via Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
 
Via Benzinga
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
From Emergent BioSolutions
Via Globe NewsWire
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
From Emergent BioSolutions
Via Globe NewsWire
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via Globe NewsWire
Ranking the 7 Top Small-Cap Stocks to Buy From Best to Worst
Although blue chips provide greater predictability, these top small-cap stocks to buy may drive intense growth for speculators. 
Via InvestorPlace
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
From Emergent BioSolutions
Via Globe NewsWire
Emergent Shares Decline Following Commencement Of Initial-Stage Lassa Virus Vaccine Candidate Study
Emergent BioSolutions (NYSE: EBS) has dosed first patient in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV in healthy subjects. EBS-LASV is a recombinant VSV-vectored Lassa... 
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
 
Via Benzinga
3 Top Monkeypox Stocks to Buy Right Now
With cases of a frightening disease spreading to all 50 states, it’s now time to consider the top monkeypox stocks to buy right now. 
Via InvestorPlace
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply. 
Via Benzinga
Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test
 
Via Benzinga
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.